Background {#Sec1}
==========

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common and serious complication of cardiac surgery \[[@CR1]\]. Depending on its severity and differences in both baseline characteristics and type of cardiac surgical procedure, the range of incidence of CSA-AKI is between 3.0 and 50.0% when applying Kidney Disease\|Improving Global Outcomes (KDIGO)-like criteria \[[@CR2]--[@CR6]\]. CSA-AKI treated with renal replacement therapy (RRT) presents post-operatively in 2.0--6.0% of cardiac surgery patients \[[@CR5], [@CR7], [@CR8]\], of which 1 out of 2 die in hospital \[[@CR5]\]. Importantly, also when the injury is mild, CSA-AKI is independently associated with significant effects on early \[i.e. hospital or 30-day (d)\] mortality \[[@CR9], [@CR10]\].

Risk for CSA-AKI is increased by the presence of established pre-operative \[e.g. increased serum creatinine (SCr)\] and peri-operative (e.g. low cardiac output) factors that increase susceptibility to AKI \[[@CR11], [@CR12]\]. Moreover, potentially important modifiable intra-operative susceptibilities are the type of cardiac surgical technique and, if cardiopulmonary bypass \[CPB; synonym: extracorporeal circulation (ECC)\] is used, the characteristics of the perfusion technique \[[@CR13]\]. Early CSA-AKI occurs within 7 d after the cardiac surgical procedure and is directly related to it \[[@CR14]\]. CSA-AKI more than 1 week but within 30 d after the cardiac surgical procedure is mainly related to another exposure that presents as a complication of the cardiac surgical procedure (e.g. sepsis) \[[@CR14]\].

Only recently the term 'acute kidney stress' (AKS) was proposed to describe the pre-injury phase that leads to AKI \[[@CR15]\]. Biomarkers, or 'measurable and quantifiable biological parameters' \[[@CR16]\], that respond to AKS open new horizons in regard to the prediction and early detection of emerging AKI. These biomarkers serve as surrogate measurements, estimating renal cell perfusion, function or metabolism \[[@CR15]\]. As regulator of the iron metabolism, neutrophil gelatinase-associated lipocalin (NGAL) measured in blood or urine represents a way to monitor initial damage \[[@CR17]\], which was confirmed in more than 7000 paediatric and adult patients who underwent cardiac surgery \[[@CR18]--[@CR20]\]. Recently, our group demonstrated the role of urinary chitinase 3-like protein 1 (UCHI3L1) as predictor of AKI in an adult general intensive care unit (ICU) cohort, with a performance similar to that of UNGAL \[[@CR21]\].

Higher systemic concentrations of CHI3L1 have been independently associated with the presence of coronary artery disease, seeming a quantitative indicator of disease progression as well \[[@CR22]\]. Additionally, it was shown that in patients with type 1 and type 2 diabetes mellitus higher systemic concentrations of CHI3L1 were associated with progressing vascular damage in the kidneys, as assessed by the level of albuminuria \[[@CR22]\]. It seems plausible that low-grade inflammation and endothelial dysfunction progressing to micro- and macrovascular complications account for higher systemic concentrations of CHI3L1. Besides a marker of chronic inflammation, systemic CHI3L1 is a marker of acute inflammation as well \[[@CR23]\]. Cardiac surgery and the use of CPB have a critical role in inducing the systemic inflammatory response syndrome leading to CSA-AKI. Consequently, SCHI3L1 can be proposed as a potential AKI risk factor.

The objectives of this study were:To evaluate whether UCHI3L1 can be used to predict occurrence of AKI in adult patients who underwent elective cardiac surgery,To compare this predictive ability with that of UNGAL, a well-known biomarker of tubular damage, and that of more frequently assessed early measurements of SCr, a routine biomarker of kidney dysfunction,To evaluate whether combining either two urinary renal stress or damage biomarkers, or a systemic kidney dysfunction biomarker and a urinary renal stress or damage biomarker can improve the predictive ability for CSA-AKI,To evaluate whether combining SCHI3L1 with either a systemic kidney dysfunction biomarker or a urinary renal stress or damage biomarker can improve the predictive ability for CSA-AKI.

Methods {#Sec2}
=======

This research is reported according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) Statement (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1) \[[@CR24]\].

Defining AKI {#Sec3}
------------

AKI was diagnosed and classified according to the KDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and urine output (UO) (Additional file [2](#MOESM2){ref-type="media"}: Fig. S2) \[[@CR25]\].

Study patients {#Sec4}
--------------

In this single-centre cohort study, we prospectively enrolled patients who were admitted to the eight-bed cardiac surgery ICU of Ghent University Hospital from May 2012 till February 2014. The inclusion and exclusion criteria of the study are incorporated in the flow diagram in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram of patient enrolment and primary endpoint analysis. ^a^Planned ≥4 h in advance. ^b^KDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO \[[@CR25]\]. ^c^KDOQI definitions for the diagnosis and staging of CKD \[[@CR40]\]. ^d^≤3 mo before. *AKI* acute kidney injury, *CKD* chronic kidney disease, *d* day, *h* hour, *ICU* intensive care unit, *KDIGO* Kidney Disease\|Improving Global Outcomes, *KDOQI* Kidney Disease Outcomes Quality Initiative, *mo* month, *No.* number, *Sat* Saturday, *SCr* serum creatinine, *Sun* Sunday, *UO* urine output, *y* year

Primary endpoint {#Sec5}
----------------

The primary endpoint of the current study was the development of AKI stage ≥1 within 48 h after t1. Reference SCr, representing baseline SCr, was defined as the lowest SCr value within the last 3 months (mo) prior to enrolment (lowest of history SCr value(s) and pre-operative SCr). In our cohort 30.0% of the patients had only the pre-operative SCr value available. In 49.3% the lowest history SCr was lower than or equal to the pre-operative SCr, while in 20.7% the pre-operative SCr was lower than the lowest history SCr. The details for calculation of UO are outlined by our group \[[@CR21]\]. Note that UO was registered hourly in the ICU only.

Secondary endpoint {#Sec6}
------------------

The secondary endpoint was AKI stage ≥2 within 12 h after t1.

Ethics approval and consent to participate {#Sec7}
------------------------------------------

The Ethical Committee of Ghent University Hospital approved this study (Belgian Registration Number of the study: B670201213147). All patients or their legally authorized representatives provided written informed consent. We respected the Declaration of Helsinki and the Good Clinical Practice Guidelines.

Prospective sample and data collection {#Sec8}
--------------------------------------

The first collection of blood and urine was after the induction of anaesthesia and before the start of surgery \[time 0 (t0) on the day of surgery (d~surgery~)\]. The rest of the specimens (*n* = 7) were collected post-operatively, starting at ICU admission (t1) and then at 2 hours (h) (t2), 4 h (t3), 6 h, 12 h, 24 h and 48 h after ICU admission. If the patient was discharged to the Midcare unit before 24 h or 48 h, those samples were collected there. Whenever possible, the routine collection times were followed \[at 4 PM on the first post-operative day (d~1post-op~) and at 6 AM on the second post-operative day (d~2post-op~)\]. The sample collection times for a fictional patient who underwent surgery in the morning are outlined on the timeline in Additional file [3](#MOESM3){ref-type="media"}: Fig. S3A, while those for a fictional patient who underwent surgery in the afternoon are outlined on the timeline in Additional file [4](#MOESM4){ref-type="media"}: Fig. S3B.

These paired blood and urine samples were collected by standard methods and centrifuged by standard protocols, as described previously by our group \[[@CR21]\]. Serum and urine supernatants were stored at −80 °C and thawed at room temperature immediately prior to analysis. Clinical data needed to complete the individual clinical research files (Additional file [5](#MOESM5){ref-type="media"}: Table S1) were extracted from the hospital records by study coordinators. Note that Additional file [5](#MOESM5){ref-type="media"} contains Tables S1, S2, S3, S4A, B, C, D and the legends of Figures S1, S2, S3A, B, S4, S5, S6. Samples were anonymized as were clinical data. All technicians were blinded to clinical data.

Biomarker analysis and single-biomarker diagnostic test possibilities {#Sec9}
---------------------------------------------------------------------

The CHI3L1 analysis was performed in-house. We measured the concentration of CHI3L1 by a sandwich enzyme-linked immunosorbent assay (ELISA) technique (DC3L10, R&D Systems, Minneapolis, MN, USA). Analyses performed externally were Cr and UNGAL. The Cobas c502 measured the concentration of Cr by a kinetic rate-blanked Jaffé assay (commercial reagents, Roche Diagnostics, Basel, Switzerland), whereas the Modular P measured the concentration of UNGAL by a particle-enhanced turbidimetric immunoassay (ST001-3CA, BioPorto, Hellerup, Denmark). All details were recently described \[[@CR21]\], except for the standard sample dilution scheme used in the CHI3L1 ELISA, which is presented in Additional file [5](#MOESM5){ref-type="media"}: Table S2. For blood samples that were collected at routine collection times, a SCr concentration was already available in the hospital records. Based on the temporal relationship of the predictive value of UNGAL for CSA-AKI \[[@CR19]\], we measured this biomarker at t1 and t3 only.

Besides UCHI3L1 and UNGAL, we also evaluated UCHI3L1 and UNGAL corrected for urine dilution by using the ratio to UCr as diagnostic test. Besides SCr, we also evaluated ΔSCr~tx-t0~ as diagnostic test, representing the absolute change in SCr between SCr~tx~ and SCr~t0~. The most recent SCr value recorded prior to surgery was considered as SCr~t0~.

Defining acute tubular damage and subclinical AKI {#Sec10}
-------------------------------------------------

Following the recommendations of de Geus et al., acute tubular damage was defined as a CSA-NGAL score of 2 or greater; either as UNGAL~t1~ or UNGAL~t3~ ≥ 150 ng/ml or as ∆UNGAL~t3-t1~ \> 100 ng/ml with UNGAL~t3~ ≥ 125 ng/ml \[[@CR26]\]. Subclinical AKI was defined when there was acute tubular damage (according to the 'de Geus criteria') and absence of AKI according to the KDIGO definition.

Defining good and excellent biomarkers {#Sec11}
--------------------------------------

An area under the receiver operating characteristics curve (AUC-ROC) of 0.750 or greater was considered to represent a good biomarker, whereas an AUC-ROC of 0.900 or greater was considered to represent an excellent biomarker \[[@CR27]\].

Statistical analysis {#Sec12}
--------------------

The principal statistical analysis was based on comparison of the AUC-ROCs of UCHI3L1 with those of UNGAL, more frequently assessed early measurements of SCr, and various two-biomarker panels for predicting both defined endpoints. It was performed in MedCalc 15.2.1 (MedCalc Software, Oostende, Belgium). The unpaired comparison of a variable between two independent samples was done in SPSS 22 (IBM, Armonk, NY, USA). Categorical variables were analysed with Fisher's exact or the Chi-square test, and continuous variables with the nonparametric Mann--Whitney *U* test. Additionally, we calculated the 95% confidence interval (CI) for a proportion using the Wilson procedure without a correction for continuity \[[@CR28], [@CR29]\]. For all analyses, two-sided *P* values \<0.05 were considered statistically significant. All details and a description of how the biomarkers were introduced into the statistical programs are provided in our previous work \[[@CR21]\].

Results {#Sec13}
=======

Incidence of the primary endpoint, characteristics of the patients and procedures, and short-term patient outcomes {#Sec14}
------------------------------------------------------------------------------------------------------------------

The flow of patients during the study is illustrated in Fig. [1](#Fig1){ref-type="fig"}. The initial enrolment cohort consisted of 211 patients. In the primary endpoint analysis, 8 patients who already had AKI stage ≥1 at t0 (*n* = 3) or t1 were excluded, resulting in a total number of 203 patients for analysis. Within 48 h after t1, 95 patients (46.8%) had developed AKI: 67 (70.5%) were classified as stage 1, 19 (20.0%) as stage 2 and 9 (9.5%) as stage 3. Three patients received RRT starting on d~2post-op~. Duration of RRT was 3 d in 2 patients and 14 d in 1 patient. The flow of patients over different diagnostic windows for AKI is illustrated in Fig. [1](#Fig1){ref-type="fig"}. The limited extent to which the UO criterion identified AKI patients is illustrated in Additional file [6](#MOESM6){ref-type="media"}: Fig. S4. Median time to AKI diagnosis was 12.2 h \[interquartile range (IQR) 7.2--18.4 h\]. Subclinical AKI, which was missed by KDIGO, occurred in 5.1% of the patients (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Combining functional and damage biomarkers simultaneously to delineate the spectrum of AKI. Patients of the primary analysis cohort (*n* = 203) who had no UNGAL~t1~ or UNGAL~t3~ concentration available were excluded. Missing UNGAL~t1~ occurred in 5 patients, and missing UNGAL~t3~ in 1 patient, resulting in a total of 197 patients. Following the recommendations of de Geus et al., acute tubular damage was defined as a CSA-NGAL score of 2 or greater; either as UNGAL~t1~ or UNGAL~t3~ ≥ 150 ng/ml or as ∆UNGAL~t3−t1~ \> 100 ng/ml with UNGAL~t3~ ≥ 125 ng/ml \[[@CR26]\]. Subclinical AKI was defined when there was acute tubular damage (according to the 'de Geus criteria') and absence of AKI according to the KDIGO definition. In this way 84.6% of AKI in our specific cohort (i.e. 77/\[77 + 14\]) was classified as AKI without acute tubular damage. Subclinical AKI, which was missed by KDIGO, occurred in 5.1% of the patients. *AKI* acute kidney injury, *CSA* cardiac surgery-associated, *d* day, *KDIGO* Kidney Disease\|Improving Global Outcomes, *t1* time of intensive care unit admission, *t3* 4 h after intensive care unit admission, *UNGAL* urinary neutrophil gelatinase-associated lipocalin

Table [1](#Tab1){ref-type="table"} summarizes the characteristics of the patients and procedures at baseline. Compared with patients without AKI, patients who developed AKI within 48 h after t1 were older; had a higher body mass index (BMI); a lower eGFR; a higher prevalence of diabetes mellitus (DM) type 2; a higher predicted operative mortality, which was estimated by the simple additive European system for cardiac operative risk evaluation (EuroSCORE); more combined surgical procedures; and a higher prevalence of diuretic treatment at home.Table 1Characteristics of the patients and procedures at baseline, as well as short-term patient outcomesNo. (%)\
\[95% CI\]All patients\
203 (100)\
\[98.1--100\]AKI stage ≥1^a^ within 48 h\
95 (46.8)\
\[40.1--53.7\]No AKI^a^ within 48 h\
108 (53.2)\
\[46.3--59.9\]*P* value*Characteristic*Male sex---no. (%) \[95% CI\]133 (65.5)\
\[58.7--71.7\]65 (68.4)\
\[58.5--76.9\]68 (63.0)\
\[53.6--71.5\]0.461White race---no. (%) \[95% CI\]202 (99.5)\
\[97.3--99.9\]95 (100)\
\[96.1--100\]107 (99.1)\
\[94.9--99.8\]1.000Age^b^ (IQR)---years70.0 (61.0--76.0)74.0 (65.0--80.0)67.0 (58.0--75.0)\<0.001BMI (IQR)27 (24--29)27 (25--31)26 (23--29)0.004*Medical history*Reference renal function (IQR) SCr---mg/dl0.90 (0.75--1.05)0.99 (0.81--1.16)0.82 (0.70--0.95)\<0.001 eGFR~CKD-EPI~---ml/min/1.73 m^2^82 (64--94)73 (54--85)87 (77--97)\<0.001DM---no. (%) \[95% CI\]0.025 Type 12 (1.0)\
\[0.3--3.5\]2 (2.1)\
\[0.6--7.4\]0 (0.0)\
\[0.0--3.4\] Type 246 (22.7)\
\[17.4--28.9\]28 (29.5)\
\[21.2--39.3\]18 (16.7)\
\[10.8--24.8\] No DM155 (76.4)\
\[70.1--81.7\]65 (68.4)\
\[58.5--76.9\]90 (83.3)\
\[75.2--89.2\]Heart failure---no. (%) \[95% CI\]0.252 NYHA class I145 (71.4)\
\[64.9--77.2\]64 (67.4)\
\[57.4--76.0\]81 (75.0)\
\[66.1--82.2\] NYHA class II36 (17.7)\
\[13.1--23.6\]17 (17.9)\
\[11.5--26.8\]19 (17.6)\
\[11.6--25.8\] NYHA class III20 (9.9)\
\[6.5--14.7\]12 (12.6)\
\[7.4--20.8\]8 (7.4)\
\[3.8--13.9\] NYHA class IV2 (1.0)\
\[0.3--3.5\]2 (2.1)\
\[0.6--7.4\]0 (0.0)\
\[0.0--3.4\]*Clinical examination*Blood pressure (IQR)---mm Hg Systolic134 (122--149)132 (122--150)134 (120--149)0.704 Diastolic72 (64--78)72 (63--78)71 (66--78)0.619 Mean93 (85--101)92 (84--102)93 (86--100)0.734Heart rhythm---no. (%) \[95% CI\]0.074 Atrial fibrillation16 (7.9)\
\[4.9--12.4\]11 (11.6)\
\[6.6--19.6\]5 (4.6)\
\[2.0--10.4\] Normal sinus rhythm187 (92.1)\
\[87.6--95.1\]84 (88.4)\
\[80.4--93.4\]103 (95.4)\
\[89.6--98.0\] Heart rate in normal sinus rhythm (IQR)---bpm\
(*N* = 187)69 (61--79)70 (62--81)69 (60--76)0.143Distribution of ejection fraction---no. (%) \[95% CI\]0.531 ≤20%5 (2.5)\
\[1.1--5.6\]4 (4.2)\
\[1.6--10.3\]1 (0.9)\
\[0.2--5.1\] 21--30%3 (1.5)\
\[0.5--4.3\]2 (2.1)\
\[0.6--7.4\]1 (0.9)\
\[0.2--5.1\] 31--50%33 (16.3)\
\[11.8--22.0\]16 (16.8)\
\[10.6--25.6\]17 (15.7)\
\[10.1--23.8\] \>50%119 (58.6)\
\[51.7--65.2\]55 (57.9)\
\[47.8--67.3\]64 (59.3)\
\[49.8--68.1\]*Index surgical procedure*EuroSCORE (IQR)5 (3--8)6 (4--9)5 (2--7)0.004Type of cardiac surgical procedure---no. (%) \[95% CI\]0.005 Isolated CABG93 (45.8)\
\[39.1--52.7\]34 (35.8)\
\[26.9--45.8\]59 (54.6)\
\[45.2--63.7\] Isolated valve repair or replacement55 (27.1)\
\[21.4--33.6\]28 (29.5)\
\[21.2--39.3\]27 (25.0)\
\[17.8--33.9\] CABG and valve repair or replacement34 (16.7)\
\[12.2--22.5\]25 (26.3)\
\[18.5--36.0\]9 (8.3)\
\[4.4--15.1\] Aortic root12 (5.9)\
\[3.4--10.0\]5 (5.3)\
\[2.3--11.7\]7 (6.5)\
\[3.2--12.8\] Other9 (4.4)\
\[2.3--8.2\]3 (3.2)\
\[1.1--8.9\]6 (5.6)\
\[2.6--11.6\]ECC---no. (%) \[95% CI\]0.516 Yes179 (88.2)\
\[83.0--91.9\]82 (86.3)\
\[78.0--91.8\]97 (89.8)\
\[82.7--94.2\] No24 (11.8)\
\[8.1--17.0\]13 (13.7)\
\[8.2--22.0\]11 (10.2)\
\[5.8--17.3\] Duration of ECC (IQR)---min\
*N* = 17991.5 (70.8--123.3)92.0 (70.3--131.3)91.5 (70.3--117.8)0.527 Priming volume of ECC pump (IQR)---ml\
*N* = 1791300 (1200--1500)1300 (1200--1500)1300 (1150--1400)0.246 Duration of aortic clamp during ECC (IQR)---min\
*N* = 17956.0 (42.8--82.0)62.0 (45.0--88.0)55.0 (40.5--74.5)0.174 Duration of ischaemia during ECC (IQR)---min\
*N* = 17954.0 (39.0--78.0)61.0 (43.0--81.0)52.0 (37.8--70.5)0.164 Duration of surgery (IQR)---h4.6 (3.9--5.2)4.7 (3.9--5.3)4.5 (3.9--5.1)0.196 IABP peri-operatively---no. (%) \[95% CI\]7 (3.4)\
\[1.7--6.9\]2 (2.1)\
\[0.6--7.4\]5 (4.6)\
\[2.0--10.4\]0.452*Medication---no. (%) \[95% CI\]*Statins127 (62.6)\
\[55.7--68.9\]63 (66.3)\
\[56.3--75.0\]64 (59.3)\
\[49.8--68.1\]0.313ACE inhibitors56 (27.6)\
\[21.9--34.1\]28 (29.5)\
\[21.2--39.3\]28 (25.9)\
\[18.6--34.9\]0.638ARBs7 (3.4)\
\[1.7--6.9\]6 (6.3)\
\[2.9--13.1\]1 (0.9)\
\[0.2--5.1\]0.052Diuretics51 (25.1)\
\[19.7--31.5\]36 (37.9)\
\[28.8--47.9\]15 (13.9)\
\[8.6--21.7\]\<0.001NSAIDs4 (2.0)\
\[0.8--5.0\]1 (1.1)\
\[0.2--5.7\]3 (2.8)\
\[0.9--7.9\]0.624Corticosteroids13 (6.4)\
\[3.8--10.6\]8 (8.4)\
\[4.3--15.7\]5 (4.6)\
\[2.0--10.4\]0.390Tacrolimus0 (0.0)\
\[0.0--1.9\]0 (0.0)\
\[0.0--3.9\]0 (0.0)\
\[0.0--3.4\]NACyclosporine2 (1.0)\
\[0.3--3.5\]2 (2.1)\
\[0.6--7.4\]0 (0.0)\
\[0.0--3.4\]0.218Aminoglycosides3 (1.5)\
\[0.5--4.3\]1 (1.1)\
\[0.2--5.7\]2 (1.9)\
\[0.5--6.5\]1.000Corticosteroids intra-operatively0 (0.0)\
\[0.0--1.9\]0 (0.0)\
\[0.0--3.9\]0 (0.0)\
\[0.0--3.4\]NAIodinated contrast ≤72 h before surgery37 (18.2)\
\[13.5--24.1\]14 (14.7)\
\[9.0--23.2\]23 (21.3)\
\[14.6--29.9\]0.275*Outcomes*RRT in ICU---no. (%) \[95% CI\]3 (1.5)\
\[0.5--4.3\]3 (3.2)\
\[1.1--8.9\]0 (0.0)\
\[0.0--3.4\]0.101ICU LOS (IQR)---d1 (1--3)2 (1--3)1 (1--2)\<0.001Hospital LOS (IQR)---d12 (9--16)13 (10--20)10 (9--13)\<0.001*ACE* angiotensin-converting enzyme, *AKI* acute kidney injury, *ARB* angiotensin-II receptor blocker, *BMI* body mass index, *bpm* beats per minute, *CABG* coronary artery bypass grafting, *CI* confidence interval, *CKD*-*EPI* Chronic Kidney Disease Epidemiology Collaboration, *DM* diabetes mellitus, *ECC* extracorporeal circulation, *eGFR* estimated glomerular filtration rate, *EuroSCORE* European system for cardiac operative risk evaluation, *h* hour, *IABP* intra-aortic balloon pump, *ICU* intensive care unit, *IQR* interquartile range, *KDIGO* Kidney Disease\|Improving Global Outcomes, *LOS* length of stay, *min* minute, *no.* number, *NSAID* nonsteroidal anti-inflammatory drug, *NYHA* New York Heart Association, *RRT* renal replacement therapy, *SCr* serum creatinine, *UO* urine output^a^KDIGO definitions for the diagnosis and staging of AKI, which are based on SCr and UO^b^Determined at the day of surgery

Peri-operative characteristics of the patients and procedures are provided in Additional file [5](#MOESM5){ref-type="media"}: Table S3. In comparison with patients without AKI, patients who developed AKI within 48 h after t1 had a higher Sepsis-related Organ Failure Assessment (SOFA) score; a higher white blood cell (WBC) count; a higher serum C-reactive protein (CRP) concentration; a more positive fluid balance; a higher number of plasma units that were transfused; and a higher prevalence of vasopressor, milrinone and diuretic treatment.

AKI patients had a longer ICU and hospital length of stay (LOS) (Table [1](#Tab1){ref-type="table"}).

Incidence of the secondary endpoint {#Sec15}
-----------------------------------

In the secondary endpoint analysis, 1 patient who already had AKI stage ≥2 at t0 was excluded, resulting in a total number of 210 patients for analysis. Within 12 h after t1, 5 patients (2.4%) had developed AKI stage ≥2: all 5 (100%) were classified as stage 2. The flow of patients over different diagnostic windows for AKI stage ≥2 is illustrated in Additional file [7](#MOESM7){ref-type="media"}: Fig. S5.

Biomarker performances for prediction of the primary endpoint {#Sec16}
-------------------------------------------------------------

In the early post-operative period, only the functional biomarker SCr was a good predictor of AKI within 48 h after t1, showing the highest AUC-ROC at t3 (0.792; 95% CI 0.728--0.847; Fig. [3](#Fig3){ref-type="fig"}). The information in Fig. [3](#Fig3){ref-type="fig"} is summarized in numerical format in Additional file [5](#MOESM5){ref-type="media"}: Tables S4B, C and D, including also the performances of the urinary renal stress or damage biomarkers corrected for urine dilution by using the ratio to UCr. Table S4A reports the performances of the biomarkers measured at t0.Fig. 3Biomarker performances for prediction of AKI. Blue boxes correspond with the primary endpoint (i.e. AKI stage ≥1 within 48 h after t1), orange boxes with the secondary endpoint (i.e. AKI stage ≥2 within 12 h after t1). ΔSCr represents ΔSCr~tx-t0~, which is the absolute change in SCr between SCr~tx~ and SCr~t0~. Biomarkers were measured **a** at ICU admission (t1), **b** 2 h after ICU admission (t2) and **c** 4 h after ICU admission (t3). *AKI* acute kidney injury, *h* hour, *ICU* intensive care unit, *SCHI3L1* serum chitinase 3-like protein 1, *SCr* serum creatinine, *UCHI3L1* urinary chitinase 3-like protein 1, *UNGAL* urinary neutrophil gelatinase-associated lipocalin

Biomarker performances for prediction of the secondary endpoint {#Sec17}
---------------------------------------------------------------

In the early post-operative period, SCHI3L1 combined with a urinary renal stress or damage biomarker, either UCHI3L1 or UNGAL, was a good predictor of AKI stage ≥2 within 12 h after t1, showing the highest AUC-ROC at t2 when combined with UCHI3L1 (0.773; 95% CI 0.708--0.829) and at t3 when combined with UNGAL (0.774; 95% CI 0.710--0.830). However, the functional biomarkers SCr and ΔSCr~tx-t0~ outperformed these combinations with good to excellent performances, showing the highest AUC-ROC at t3 (0.857 for SCr; 95% CI 0.801--0.902; 0.938 for ΔSCr~tx−t0~; 95% CI 0.860--1.000; Fig. [3](#Fig3){ref-type="fig"}). The information in Fig. [3](#Fig3){ref-type="fig"} is summarized in numerical format in Additional file [5](#MOESM5){ref-type="media"}: Tables S4B, C and D, including also the performances of the urinary renal stress or damage biomarkers corrected for urine dilution by using the ratio to UCr. Table S4A reports the performances of the biomarkers measured at t0.

Discussion {#Sec18}
==========

We found that in adult patients who underwent elective cardiac surgery, UCHI3L1 had inadequate predictive value for CSA-AKI. This was also true for the well-known tubular damage biomarker UNGAL. In contrast, more frequent assessment of the functional biomarker SCr in the early post-operative ICU period (first 4 h) had good to excellent predictive value for CSA-AKI.

Similar to others, our ICU routinely measures SCr at t1 and either around t4 (morning patient) or t5 (afternoon patient) in the early post-operative period. However, with ±50% of AKI diagnosed before t5, of which ±50% before t4, our study highlights the importance of more frequent SCr assessment in the first 4 h. This aids in early AKI diagnosis and could also reveal some cases of rapid reversal of AKI (i.e. 'complete reversal of AKI by KDIGO criteria within 48 h of AKI onset' \[[@CR30]\]). These findings are in accordance with those of a small retrospective study (*n* = 29) by Maciel et al. \[[@CR31]\].

Novel findings of our study are the good to excellent performances of ΔSCr~t1−t0~, ΔSCr~t2−t0~ and ΔSCr~t3−t0~ for the prediction of AKI stage ≥2 within 12 h after t1. In accordance with these results, measurement of very early post-operative SCr changes, either absolute \[[@CR10]\] or relative \[[@CR32], [@CR33]\], in adult \[[@CR10], [@CR33]\] and paediatric \[[@CR32]\] cardiac surgery patients has been reported to provide prognostic utility for a subsequent diagnosis of AKI. However, each of these three studies was restricted by some of the following limitations: AKI was not defined according to KDIGO, including oliguric criteria; more severe AKI was not included as endpoint; SCr was less frequently assessed in the early post-operative period; and AUC-ROC analysis was not reported.

The simultaneous utilization of functional and damage biomarkers, as in the CSA-NGAL score \[[@CR26]\], permits to delineate the spectrum of AKI \[[@CR34]\]. In this way 84.6% of AKI in our specific cohort (i.e. 77/\[77 + 14\]) was classified as AKI without acute tubular damage. The capacity of the kidneys to increase baseline GFR under physiological or pathological kidney stress is described by the renal functional reserve of the glomerular function (Additional file [8](#MOESM8){ref-type="media"}: Fig. S6) \[[@CR35]\]. In congestive heart failure, CKD and AKI, utilization of the renal functional reserve of the glomerular function allows to replace (in part) the lost function, maintaining a normal whole-organ baseline GFR until ±50% of the nephrons are nonfunctional. The presence of an intact renal functional reserve of the glomerular function and nephron mass guarantees a low renal frailty or susceptibility \[[@CR36]\]. Compared with the general ICU cohort of our previous AKI biomarker study \[[@CR21]\], the patients in this study were older (median 70.0 vs. 60.0 y), more often diabetic (median 23.6 vs. 7.2%), had a higher BMI (median 27 vs. 24) and a lower baseline eGFR (median 82 vs. 102 ml/min/1.73 m^2^). We therefore hypothesize that a lower renal functional reserve of the glomerular function and nephron mass in this population caused the low incidence of both subclinical AKI and AKI with acute tubular damage. This can also explain the inadequate performance of the urinary renal stress or damage biomarkers UCHI3L1 and UNGAL for prediction of AKI stage ≥2 within 12 h after t1. Our study is, however, not the first to report inadequate diagnostic ability of UNGAL for moderate to severe CSA-AKI \[[@CR20]\]. In their multicentre high-risk cohort with 21% emergent surgeries, 42% diabetic patients and a baseline eGFR of 67 ml/min/1.73 m^2^, Parikh et al. reported an AUC-ROC of 0.67 (standard error (SE) 0.04) for the prediction of AKI defined by receipt of RRT or doubling of SCr \[[@CR37]\]. Interestingly, Koyner et al. found an AUC-ROC of 0.88 (95% CI 0.73--0.99) for the prediction of AKI Acute Kidney Injury Network (AKIN) stage 3 in a cohort comparable to ours \[[@CR38]\], indicating the importance of the severity of AKI in the predictive ability of UNGAL.

Our study has several limitations. First, it is limited in being a single-centre study in elective cardiac surgery patients. However, baseline characteristics and the incidence of AKI suggest that our population is representative of cardiac surgery ICUs in developed countries. Second, our study is further limited by the relatively low incidence of AKI stage ≥2 within 12 h after t1 (secondary endpoint). Both the fact that we included only elective surgeries and the implemented narrow diagnostic window contribute to this constraint. As such, these biomarker data need to be further validated in larger multicentre prospective studies. Third, we did not measure the panel of G1 cell-cycle arrest biomarkers tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) \[[@CR39]\], because it was not available at the start of our study.

Conclusions {#Sec19}
===========

In summary, we demonstrated that more frequent assessment of the functional biomarker SCr in the early post-operative ICU period (first 4 h) after elective cardiac surgery in adult patients had good to excellent predictive value for CSA-AKI, indicating that routine SCr assessment must become more frequent in order to detect AKI more early. We found that AKI was predominantly without acute tubular damage and that subclinical AKI was uncommon in this cohort. This may explain the inadequate predictive value for CSA-AKI of the urinary renal stress or damage biomarkers UCHI3L1 and UNGAL. These results need to be further validated in larger multicentre prospective studies.
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